オプションチェーンは、Orthofix Medicalの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Orthofix Medicalの市場センチメントを評価します。.

Orthofix Medical (NASDAQ:OFIX) 株価情報, オプションチェーン

Orthofix Medical

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Orthofix Medical Inc

WIIM

OFIX

Orthofix Medical shares are trading higher after the company reported better-than-expected Q3 financial results and entered into a new-credit agreement worth up to $275 million. Additionally, Stifel upgraded the stock from Hold to Buy and raised its price target from $18 to $24 while Roth MKM raised its price target from $20 to $22.

Roth MKM analyst Jason Wittes reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and raises the price target from $20 to $22.

News

Price Target

Reiteration

Analyst Ratings

Roth MKM Reiterates Buy on Orthofix Medical, Raises Price Target to $22

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) price target from $110 to $140. Piper Sandler analyst Matt Farrell reiterated an Overweight rating. Trade Desk shares closed at $132.53 on Wednesday. See how other analysts view this stock.</li>
<li>Scotiabank raised the price target for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from $85 to $87. Scotiabank analyst Patrick Colville maintained a Sector Perform rating. Cloudflare shares closed at $95.66 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $19 to $41. Wells Fargo analyst Stan Berenshteyn upgraded the stock from Underweight to Equal-Weight. Doximity shares closed at $43.42 on Thursday. <a href="https://www.benzinga.com/quote/DOCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) price target from $39 to $37. Baird analyst Colin Sebastian maintained a Neutral rating. Yelp shares settled at $36.37 on Thursday. <a href="https://www.benzinga.com/quote/YELP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) price target from $275 to $305. Telsey Advisory Group analyst Joseph Feldman upgraded the stock from Market Perform to Outperform. Lowe&#8217;s shares closed at $266.30 on Thursday. <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) price target from $80 to $88. Baird analyst Shrenik Kothari maintained an Outperform rating. Fortinet shares closed at $83.68 on Thursday. <a href="https://www.benzinga.com/quote/FTNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised the price target for Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from $28 to $40. Citigroup analyst Steven Zaccone upgraded the stock from Neutral to Buy. Chewy shares settled at $30.79 on Thursday. <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) price target from $230 to $280. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Veeva shares closed at $223.39 on Thursday. <a href="https://www.benzinga.com/quote/VEEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from $18 to $24. Stifel analyst Mathew Blackman upgraded the stock from Hold to Buy. Orthofix Medical shares closed at $18.22 on Thursday. <a href="https://www.benzinga.com/quote/OFUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Under Armour, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) price target from $8 to $10. Baird analyst Jonathan Komp maintained a Neutral rating. Under Armour shares closed at $11.13 on Thursday. <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CHWY

DOCS

FTNT

VEEV

YELP

Lowe's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Friday

Stifel analyst Mathew Blackman upgrades Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from Hold to Buy and raises the price target from $18 to $24.

Upgrades

Stifel Upgrades Orthofix Medical to Buy, Raises Price Target to $24

Health Care

Financing

General

Orthofix Medical Announced The Entry Into A New Credit Agreement Providing The Company With Up To $275M In A Senior-secured Term Loan With A 48-month Interest Only Period

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) affirms FY2024 sales outlook from $795.00 million-800.00 million to $795.00 million-800.00 million.

Guidance

Orthofix Medical Affirms FY2024 Sales Guidance from $795.00M-800.00M to $795.00M-800.00M

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.15) by 146.67 percent. The company reported quarterly sales of $196.606 million which beat the analyst consensus estimate of $196.522 million by 0.04 percent. This is a 6.85 percent increase over sales of $184.006 million the same period last year.

Earnings

Earnings Beats

Orthofix Medical Q3 2024 Adj. EPS $0.07 Beats $(0.15) Estimate, Sales $196.606M Beat $196.522M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Forthofix.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=Orthofix+Medical+Inc&amp;index=1&amp;md5=f980520f95bd1a9234c20487cdf8b284">Orthofix Medical Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbonegrowththerapy.com%2Ftherapies%2Fspinal-fusion%2Fspinalstim-lumbar-fusion%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=SpinalStim&amp;index=2&amp;md5=c26f0cc0fb348022b3ce0b675596e790">SpinalStim</a>&#x2122; bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.
The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center.
During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand&#x2122; Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell&#x2122; Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips. Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fm6disc.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=M6-C&amp;index=3&amp;md5=0f2300dfde3b2d3c8390c084ccf90edc">M6-C</a>&#x2122; Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty.

Orthofix Unveils New Spinal Fusion Products and Data, Highlighting Innovation at NASS Annual Meeting

Orthofix Sees 2024 Net Sales $795M-$800M vs $793.79M Est.

Earnings Misses

Orthofix Medical Q2 EPS $(0.88), Sales $198.60M Beat $195.23M Estimate

The Rodeo Telescopic Nail is a&nbsp;device indicated to surgically treat deformities or fractures in patients suffering from osteogenesis imperfecta (OI). The nail implant serves to stabilize the patient&#39;s limb while also elongating (or telescoping) to accommodate the natural growth of pediatric patients.

Orthofix Medical Has Received FDA 510(K) Clearance To Market Its Rodeo Telescopic Nail

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Piper Sandler cut the price target for ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) from $24 to $15. Piper Sandler analyst Brent Bracelin downgraded the stock from Overweight to Neutral. ZoomInfo Technologies shares fell 3.6% to close at $16.02 on Tuesday. <a href="https://www.benzinga.com/quote/ZI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) from $130 to $140. Baird analyst William Power upgraded the stock from Neutral to Outperform. Datadog shares fell 11.5% to close at $112.40 on Tuesday. <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham increased MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) price target from $90 to $100. Needham analyst Kyle Peterson maintained a Buy rating. MoneyLion shares rose 0.2% to close at $71.53 on Tuesday. <a href="https://www.benzinga.com/quote/ML/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth MKM raised the price target for Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from $15 to $20. Roth MKM analyst Jason Wittes upgraded the stock from Neutral to Buy. Orthofix Medical shares rose 3.2% to close at $13.89 on Tuesday. <a href="https://www.benzinga.com/quote/OFIX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) price target from $603 to $671. Baird analyst Eric Coldwell maintained an Outperform rating. McKesson shares rose 2.3% to close at $545.75 on Tuesday. <a href="https://www.benzinga.com/quote/MCK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho increased Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) price target from $70 to $71. Mizuho analyst Nitin Kumar maintained a Neutral rating. Occidental Petroleum shares gained 0.1% to close at $65.07 on Tuesday. <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Confluent, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFLT#NASDAQ">CFLT</a>) from $28 to $35. Canaccord Genuity analyst Kingsley Crane upgraded the stock from Hold to Buy. Confluent shares fell 2.8% to close at $27.83 on Tuesday. <a href="https://www.benzinga.com/quote/CFLT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt cut Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) price target from $76 to $64. Rosenblatt analyst Andrew Bond downgraded the stock from Buy to Neutral. Nasdaq shares fell 1.1% to close at $60.90 on Tuesday. <a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities slashed Crexendo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) price target from $6.75 to $5.75. B. Riley Securities analyst Josh Nichols upgraded the stock from Neutral to Buy. Crexendo shares fell 2.1% to close at $4.65 on Tuesday. <a href="https://www.benzinga.com/quote/CXDO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler cut Jack in the Box Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) price target from $81 to $67. Piper Sandler analyst Brian Mullan maintained a Neutral rating. Jack in the Box shares rose 0.02% to close at $54.92 on Friday. <a href="https://www.benzinga.com/quote/JACK/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/05/38692433/investor-sentiment-falls-further-dow-gains-for-fifth-session">Investor Sentiment Falls Further, Dow Gains For Fifth Session</a>

CFLT

CXDO

DDOG

JACK

NDAQ

Datadog To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Wednesday

Roth MKM analyst Jason Wittes upgrades Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from Neutral to Buy and raises the price target from $15 to $20.

Roth MKM Upgrades Orthofix Medical to Buy, Raises Price Target to $20

Orthofix Cuts FY24 Revenue Outlook From $785M - $795M To $790M - $795M Vs. $790.82M Est.

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.33) by 187.88 percent. This is a 850 percent decrease over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $188.60 million which beat the analyst consensus estimate of $184.13 million by 2.43 percent. This is a 7.65 percent increase over sales of $175.20 million the same period last year.

Orthofix Medical Q1 EPS $(0.95) Misses $(0.33) Estimate, Sales $188.60M Beat $184.13M Estimate

JMP Securities analyst David Turkaly reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Market Perform.

JMP Securities Reiterates Market Perform on Orthofix Medical

Roth MKM analyst Jason Wittes maintains Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Neutral and raises the price target from $12 to $15.

Roth MKM Maintains Neutral on Orthofix Medical, Raises Price Target to $15

Orthofix Medical shares are trading higher after the company reported better-than-expected Q4 revenue results and issued FY24 net sales guidance above estimates.

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.08) by 637.5 percent. This is a 68.57 percent decrease over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $200.41 million which beat the analyst consensus estimate of $195.31 million by 2.61 percent. This is a 63.97 percent increase over sales of $122.23 million the same period last year.

Orthofix Medical Earlier Reported Q4 EPS $(0.59) Misses $(0.08) Estimate, Sales $200.41M Beat $195.31M Estimate

Non-GAAP adjusted EBITDA of&nbsp;$62 million&nbsp;to&nbsp;$67 million, representing a&nbsp;$15.7 million&nbsp;to&nbsp;$20.7 million&nbsp;increase, over the full year 2023
<div>Non-GAAP adjusted EBITDA of&nbsp;$62 million&nbsp;to&nbsp;$67 million, representing a&nbsp;$15.7 million&nbsp;to&nbsp;$20.7 million&nbsp;increase, over the full year 2023</div>

Orthofix Expects 2024 Net Sales To Range $785M-$795M (Est. $741.55M), Expects To Exit Q4 2024 Free Cash Flow Positive

Orthofix reports mixed Q2 results; raises FY24 outlook

Orthofix Medical Inc. (OFIX) Q2 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Orthofix Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/ofix-stock-quote/">OFIX</a>) just reported results for the second quarter of 2024.<ul><li>Orthofix Medical reported earnings per share of 5 cents. This was above the analyst estimate for EPS of -19 cents.</li><li>The company reported revenue of $198.62 million.</li><li>This was 1.74% better than the analyst estimate for revenue of $195.23 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ofix-stock-earnings-orthofix-medical-for-q2-of-2024/">OFIX Stock Earnings: Orthofix Medical Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OFIX Stock Earnings: Orthofix Medical Beats EPS, Beats Revenue for Q2 2024

In a report released today, David Turkaly from JMP Securities reiterated a Hold rating on Orthofix (OFIX – Research Report). The company's shares c...

JMP Securities Keeps Their Hold Rating on Orthofix (OFIX)

THE LAWSUIT: A class action securities lawsuit was filed against Orthofix Medical Inc. (OFIX) that seeks to recover losses of Orthofix shareholders...

Levi & Korsinsky LLP Notifies Orthofix Medical Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – OFIX

Orthofix GAAP EPS of -$0.71 misses by $0.37, revenue of $196.6M in-line

An announcement from Orthofix ( ($OFIX) ) is now available. Orthofix Medical Inc. reported a 7% increase in third-quarter 2024 net sales, reaching ...

Orthofix Reports Q3 Sales Growth and New Financial Targets

Reports Q3 revenue $196.606M , consensus $$196.52M ."Our third quarter net sales results were driven by focused execution of our key growth priorit...

Orthofix reports Q3 EPS (71c), consensus (15c)

Stifel analyst Mathew Blackman upgraded Orthofix (OFIX) to Buy from Hold with a price target of $24, up from $18. The firm has been "looking for an...

Orthofix upgraded to Buy at Stifel amid above end-market growth

Orthofix raised to buy by Stifel, new management cited

Legal

Press Releases

RLF, A TOP-RANKED LAW FIRM, Encourages Orthofix Medical Inc. Investors to Secure Counsel Before Important October 21 Deadline in Securities Class Action – OFIX

OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

OFIX CLASS ACTION NEWS: OrthoFix Medical Inc. Shareholders with Large Losses Should Seek Counsel; Contact Robbins LLP About the Pending Class Action Lawsuit

ORTHOFIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Orthofix Medical Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Orthofix Medical

Orthofix Medical (OFIX) オプション

Orthofix Medical (NASDAQ:OFIX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル